Oncogenex Pharmaceuticals Inc., of Bothell, Wash., said enrollment was completed in Borealis-1, a company-sponsored Phase II trial testing heat-shock protein 27 inhibitor OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. About 180 patients were recruited into the study.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter